Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab in New Onset Type 1 Diabetes
NCT00806572Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2002
- Primary completion
- Jul 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of teplizumab in type 1 diabetes mellitus (T1D) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: 4-hour C-peptide Area Under the Curve at 24 months. Started May 2002; status: terminated.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00806572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806572.